Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-031-5 | CAS number: 131-57-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
in vitro
Oxybenzone was found negative for inducing gene mutations in four in vitro studies (two Ames tests according to OECD 471, Mammalian Chromosome Aberration test according to OECD 473 and Mammalian Cells Gene Mutation test according to OECD 476), all conducted in the presence and absence of metabolic activation. The key Ames test studied five mutant strains of Salmonella typhimurium (TA1535, TA1537, TA 1538, TA98, and TA100) with and without liver homogenate (S9) as well as E. coli WP2 with and without liver homogenate (S9) in test concentrations up to 1250 µg per plate. No increase in revertant colony numbers of any of the tester strains was observed following treatment with oxybenzone at any dose level, neither in the presence nor absence of metabolic activation (S9 mix). The second supporting Ames test was performed using four strains of Salmonella typhimurium (TA1535, TA1537, TA98, and TA100) with and without liver homogenate (S9) as well as E. coli WP2 with and without liver homogenate (S9) in test concentrations up to 5000 µg per plate. In both studies there was no tendency of higher mutation rates with increasing concentrations in the range below the generally acknowledged border of biological relevance.
Appropriate reference mutagens were used as positive controls in both studies and showed a distinct increase of induced revertant colonies.
In conclusion, these results indicated that test article was not mutagenic to Salmonella typhimurium strains TA1535,TA1537, TA 1538, TA98, and TA100 or to E. coli WP2 in the absence and presence of a metabolic system.
The third in vitro study was performed to evaluate the potential to induce structural chromosomal aberrations in V79 Chinese Hamster cells in the absence and the presence of artificial sunlight (with and without metabolic activation) in two independent experiments according to OECD guideline 473. The test article was applied up to 75 µM. In the assay, based on the results given in this study, oxybenzone, was found not to induce structural chromosome aberrations in the absence or presence of artificial sunlight in V79 Chinese Hamster cells. Therefore, the test article was shown to be non-clastogenic in this chromosomal aberration photomutagenicity test when tested up to cytotoxic concentrations.
The third in vitro study was performed to investigate the potential of oxybenzone to induce gene mutations at the HPRT locus in V79 cells of the Chinese hamster according to OECD guideline 476.The test article was applied up to 2283 µg/ml in the pre-test and up to 160 µg/ml in the two main tests. No substantial and reproducible dose dependent increase of the mutation frequency was observed in either of the main experiments. Thus, the test item did not induce gene mutation effects at the HPRT locus in V79 cells.
In vivo
As all available in vitro tests were negative, in vivo data are not required.
Justification for selection of genetic toxicity endpoint
All three available key in vitro tests contribute to the final assessment for the substance being considered negative inducing gene mutations, supported by an additional Ames test.
Short description of key information:
Based on the available data, oxybenzone was found negative inducing gene mutagenicity under the experimental conditions of four in vitro tests .
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
Oxybenzone does not have to be classified for mutagenicity according to the criteria laid down in the EU Dangerous Substances Directive (67/548/EEC) and in the EU Classification Labelling and Packaging Regulation (1272/2008/EC) because it did not reveal any mutagenic effect in the bacterial reverse mutation assay in the presence or absence of metabolic activation, in the mammalian cell gene (HPRT) mutation test in V79 cells or in an in vitro chromosomal aberration test.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
